Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 108

1.

t(8;9)(p22;p24)/PCM1-JAK2 activates SOCS2 and SOCS3 via STAT5.

Ehrentraut S, Nagel S, Scherr ME, Schneider B, Quentmeier H, Geffers R, Kaufmann M, Meyer C, Prochorec-Sobieszek M, Ketterling RP, Knudson RA, Feldman AL, Kadin ME, Drexler HG, MacLeod RA.

PLoS One. 2013;8(1):e53767. doi: 10.1371/journal.pone.0053767. Epub 2013 Jan 23.

PMID:
23372669
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2.

Reiter A, Walz C, Watmore A, Schoch C, Blau I, Schlegelberger B, Berger U, Telford N, Aruliah S, Yin JA, Vanstraelen D, Barker HF, Taylor PC, O'Driscoll A, Benedetti F, Rudolph C, Kolb HJ, Hochhaus A, Hehlmann R, Chase A, Cross NC.

Cancer Res. 2005 Apr 1;65(7):2662-7.

PMID:
15805263
[PubMed - indexed for MEDLINE]
Free Article
3.

The t(8;9)(p22;p24) translocation in atypical chronic myeloid leukaemia yields a new PCM1-JAK2 fusion gene.

Bousquet M, Quelen C, De Mas V, Duchayne E, Roquefeuil B, Delsol G, Laurent G, Dastugue N, Brousset P.

Oncogene. 2005 Nov 3;24(48):7248-52.

PMID:
16091753
[PubMed - indexed for MEDLINE]
4.

Histone deacetylases inhibitor sodium butyrate inhibits JAK2/STAT signaling through upregulation of SOCS1 and SOCS3 mediated by HDAC8 inhibition in myeloproliferative neoplasms.

Gao SM, Chen CQ, Wang LY, Hong LL, Wu JB, Dong PH, Yu FJ.

Exp Hematol. 2013 Mar;41(3):261-70.e4. doi: 10.1016/j.exphem.2012.10.012. Epub 2012 Oct 27.

PMID:
23111066
[PubMed - indexed for MEDLINE]
5.

SOCS2: inhibitor of JAK2V617F-mediated signal transduction.

Quentmeier H, Geffers R, Jost E, Macleod RA, Nagel S, Röhrs S, Romani J, Scherr M, Zaborski M, Drexler HG.

Leukemia. 2008 Dec;22(12):2169-75. doi: 10.1038/leu.2008.226. Epub 2008 Sep 4.

PMID:
18769447
[PubMed - indexed for MEDLINE]
6.

Hematologic malignancies with PCM1-JAK2 gene fusion share characteristics with myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, and FGFR1.

Patterer V, Schnittger S, Kern W, Haferlach T, Haferlach C.

Ann Hematol. 2013 Jun;92(6):759-69. doi: 10.1007/s00277-013-1695-3. Epub 2013 Feb 12.

PMID:
23400675
[PubMed - indexed for MEDLINE]
7.

Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia.

Peeters P, Raynaud SD, Cools J, Wlodarska I, Grosgeorge J, Philip P, Monpoux F, Van Rompaey L, Baens M, Van den Berghe H, Marynen P.

Blood. 1997 Oct 1;90(7):2535-40.

PMID:
9326218
[PubMed - indexed for MEDLINE]
Free Article
8.

Should myeloid and lymphoid neoplasms with PCM1-JAK2 and other rearrangements of JAK2 be recognized as specific entities?

Bain BJ, Ahmad S.

Br J Haematol. 2014 Sep;166(6):809-17. doi: 10.1111/bjh.12963. Epub 2014 Jun 10. Review.

PMID:
24913195
[PubMed - indexed for MEDLINE]
9.

Multiple oligomerization domains of KANK1-PDGFRβ are required for JAK2-independent hematopoietic cell proliferation and signaling via STAT5 and ERK.

Medves S, Noël LA, Montano-Almendras CP, Albu RI, Schoemans H, Constantinescu SN, Demoulin JB.

Haematologica. 2011 Oct;96(10):1406-14. doi: 10.3324/haematol.2011.040147. Epub 2011 Jun 17.

PMID:
21685469
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Implication of MAPK1/MAPK3 signalling pathway in t(8;9)(p22;24)/PCM1-JAK2 myelodysplastic/myeloproliferative neoplasms.

Masselli E, Mecucci C, Gobbi G, Carubbi C, Pierini V, Sammarelli G, Bonomini S, Prezioso L, Rossetti E, Caramatti C, Aversa F, Vitale M.

Br J Haematol. 2013 Aug;162(4):563-6. doi: 10.1111/bjh.12392. Epub 2013 May 24. No abstract available.

PMID:
23701125
[PubMed - indexed for MEDLINE]
11.

Biallelic mutation of SOCS-1 impairs JAK2 degradation and sustains phospho-JAK2 action in the MedB-1 mediastinal lymphoma line.

Melzner I, Bucur AJ, Brüderlein S, Dorsch K, Hasel C, Barth TF, Leithäuser F, Möller P.

Blood. 2005 Mar 15;105(6):2535-42. Epub 2004 Nov 30.

PMID:
15572583
[PubMed - indexed for MEDLINE]
Free Article
12.

Suppressor of cytokine signalling-6 promotes neurite outgrowth via JAK2/STAT5-mediated signalling pathway, involving negative feedback inhibition.

Gupta S, Mishra K, Surolia A, Banerjee K.

PLoS One. 2011;6(11):e26674. doi: 10.1371/journal.pone.0026674. Epub 2011 Nov 17.

PMID:
22125600
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Ruxolitinib inhibits transforming JAK2 fusion proteins in vitro and induces complete cytogenetic remission in t(8;9)(p22;p24)/PCM1-JAK2-positive chronic eosinophilic leukemia.

Lierman E, Selleslag D, Smits S, Billiet J, Vandenberghe P.

Blood. 2012 Aug 16;120(7):1529-31. doi: 10.1182/blood-2012-06-433821. No abstract available.

PMID:
22899477
[PubMed - indexed for MEDLINE]
Free Article
14.

Differential selectivity of JAK2 inhibitors in enzymatic and cellular settings.

Yu V, Pistillo J, Archibeque I, Han Lee J, Sun BC, Schenkel LB, Geuns-Meyer S, Liu L, Emkey R.

Exp Hematol. 2013 May;41(5):491-500. doi: 10.1016/j.exphem.2013.01.005. Epub 2013 Jan 19.

PMID:
23340136
[PubMed - indexed for MEDLINE]
15.

Dynamic mathematical modeling of IL13-induced signaling in Hodgkin and primary mediastinal B-cell lymphoma allows prediction of therapeutic targets.

Raia V, Schilling M, Böhm M, Hahn B, Kowarsch A, Raue A, Sticht C, Bohl S, Saile M, Möller P, Gretz N, Timmer J, Theis F, Lehmann WD, Lichter P, Klingmüller U.

Cancer Res. 2011 Feb 1;71(3):693-704. doi: 10.1158/0008-5472.CAN-10-2987. Epub 2010 Dec 2.

PMID:
21127196
[PubMed - indexed for MEDLINE]
Free Article
16.

Polo-like kinase 1 (Plk1) is expressed by cutaneous T-cell lymphomas (CTCLs), and its downregulation promotes cell cycle arrest and apoptosis.

Nihal M, Stutz N, Schmit T, Ahmad N, Wood GS.

Cell Cycle. 2011 Apr 15;10(8):1303-11. Epub 2011 Apr 15.

PMID:
21436619
[PubMed - indexed for MEDLINE]
Free Article
17.

Fusion of EML1 to ABL1 in T-cell acute lymphoblastic leukemia with cryptic t(9;14)(q34;q32).

De Keersmaecker K, Graux C, Odero MD, Mentens N, Somers R, Maertens J, Wlodarska I, Vandenberghe P, Hagemeijer A, Marynen P, Cools J.

Blood. 2005 Jun 15;105(12):4849-52. Epub 2005 Feb 15.

PMID:
15713800
[PubMed - indexed for MEDLINE]
Free Article
18.

Chronic eosinophilic leukemia with erythroblastic proliferation and the rare translocation t(8;9)(p22;p24) with PCM1-JAK2 fusion gene: a distinct clinical, pathological and genetic entity with potential treatment target?

Prochorec-Sobieszek M, Nasiłowska-Adamska B, Borg K, Kopeć I, Kos-Zakrzewska K, Juszczyński P, Warzocha K.

Leuk Lymphoma. 2012 Sep;53(9):1824-7. doi: 10.3109/10428194.2012.661856. Epub 2012 Mar 13. No abstract available.

PMID:
22288769
[PubMed - indexed for MEDLINE]
19.

STAT5-mediated expression of oncogenic miR-155 in cutaneous T-cell lymphoma.

Kopp KL, Ralfkiaer U, Gjerdrum LM, Helvad R, Pedersen IH, Litman T, Jønson L, Hagedorn PH, Krejsgaard T, Gniadecki R, Bonefeld CM, Skov L, Geisler C, Wasik MA, Ralfkiaer E, Ødum N, Woetmann A.

Cell Cycle. 2013 Jun 15;12(12):1939-47. doi: 10.4161/cc.24987. Epub 2013 May 15.

PMID:
23676217
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Epigenetic profiling of cutaneous T-cell lymphoma: promoter hypermethylation of multiple tumor suppressor genes including BCL7a, PTPRG, and p73.

van Doorn R, Zoutman WH, Dijkman R, de Menezes RX, Commandeur S, Mulder AA, van der Velden PA, Vermeer MH, Willemze R, Yan PS, Huang TH, Tensen CP.

J Clin Oncol. 2005 Jun 10;23(17):3886-96. Epub 2005 May 16.

PMID:
15897551
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk